Genmab

	30/10 12:12 af DevOp	Lad os håbe, at der kommer en klar afgørelse på valget og at covid-frygten ikke stikker helt af inden SITC. Så skulle der da være en chance for, at det bliver en god trigger.
	30/10 11:50 af E L	I wonder what Genmab will do with Kesimpta sales for Q3, will probably leave them at 0 for now ?
	30/10 11:42 af GeorgeBest	Agree, I am really looking forward to those presentations...
	30/10 11:31 af Sukkeralf	yes its very unique - and all of them could have BB potential. But maybe even more important is the PD-L1/4-1BB data and Genmabs focus on the DuoBody platform at CMD.
	30/10 11:28 af GeorgeBest	Thanks E L. Looks like we will have 2 more Genmab developed products on the market next year. Tiso and Amivatamab. That’s a total of 5 then. 1 year ago it was only dara (Arzerra hardly contributed with revenues). Fantastic development...:-)
	30/10 11:26 af Rune2494	@pensionisten, man kan også vende den og sige, at hvis ikke det var for alle de gode nyheder, hvor langt var vi så nede nu :-)
	30/10 10:57 af E L	answer on Reni Benjamin is worth reading
	30/10 10:56 af E L	And so when we come in with our data it's the best data that we've seen in this type of patient population of relapse, cervical cancer. [] And so I look at this and say, wow, if we can have these data, single-agent what could we do if we combine it with a checkpoint or any of these other agents? "
	30/10 10:54 af E L	We and Genmab plan to submit the BLA to the FDA to support accelerated approval in this indication and to initiate a randomized confirmative trial of TV and cervical cancer in the coming months. We are also advancing clinical trials of TV monotherapy in other cancers and in combination with other agents.
	30/10 10:53 af E L	"we and Genmab recently amended specifics of the TV global commercialization plan, whereby Seagen will lead global commercial activities, except in Japan. We will continue joint decision-making on worldwide strategy and Seagen and Genmab will co-promote TV in the U.S. In addition, Seagen will lead the majority of global operational development activities.
	30/10 10:51 af E L	Seagen's (SGEN) CEO Clay Siegall on Q3 2020 Results - Earnings Call Transcript (link)
	30/10 10:41 af E L	Seagen press release (link) and presentation (link)
	30/10 10:38 af E L	which could support accelerated approval in the U.S.
	30/10 10:38 af E L	Seagen : Presented Results from Tisotumab Vedotin (TV) Pivotal Trial at ESMO: In September 2020, Seagen and Genmab presented positive results at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from the phase 2 single-arm clinical trial known as innovaTV 204. The trial is evaluating TV for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer. The companies plan to submit a BLA to the FDA,
	30/10 09:08 af transalp	Go morgen.. :)
	30/10 07:43 af Helge Larsen/PI-redaktør	God morgen. :-)
	30/10 07:36 af Plimsoller	:-)
	30/10 07:36 af Plimsoller	God morgen .-)
	29/10 21:16 af Hamming	Spændende samarbejdspartner
	29/10 21:16 af Hamming	Nyt fra Immatics (link)
	29/10 17:43 af E L	yeah, EL is the stock ticker for Estée Lauder lol (which trades over 200 so don't know where the 75.8 comes from). The funny thing is that each time somebody types it like that here, it trades down, always - . I hope that is not a reflection on me ;-)
	29/10 13:24 af E L	The multiple myeloma trial for SAR442257, an antiCD38 xCD28xCD3 trispecific antibody, dosed its first patient.
	29/10 13:24 af E L	The development of the combination of Sarclisa® and atezolizumab in squamous cell carcinoma of the head and neck has been terminated.
	29/10 13:23 af E L	Switzerland, Canada and UK. Five additional commercial launches are expected by year-end.

	29/10 13:23 af E L	Sarclisa® was approved in March in the U.S. for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and in June by the European Commission in certain adults with RRMM. Third-quarter Sarclisa® sales were €13 million of which €9 million was generated in the U.S. despite the challenging launch environment due to COVID-19. Sarclisa® is now launched in the U.S., Austria, Japan,
	29/10 13:23 af E L	Sarclisa sold 13mio in Q3, 18mio YTD
	29/10 11:15 af E L	In addition, Novartis is exploring other avenues for Kesimpta’s clinical development, including plans to test the medication in children with MS. (link) “We are not stopping research into Kesimpta,” he added. “Research continues with Kesimpta to help more patients know of its value.”
	29/10 11:15 af E L	Novartis is also starting a new trial for people with relapsing MS who switch to Kesimpta from another anti-CD20 monoclonal antibody therapy; ie. Ocrevus (link)
	29/10 10:24 af E L	we used to see ofatumumab articles for that...
	29/10 10:23 af E L	A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome (link)
	29/10 10:15 af E L	Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies (link)
	29/10 10:08 af E L	AMGEN: KYPROLIS® (carfilzomib) sales decreased 2% year-over-year driven by volume declines, as fewer new patients began treatment due to COVID-19. Early indications point to a strong launch of the new once-weekly KYPROLIS and DARZALEX® (daratumumab) combination regimen that was approved by the U.S. Food and Drug Administration (FDA) in August.
	29/10 09:54 af E L	Daratumumab efficacy in extramedullary orbital myeloma (link)
	29/10 09:48 af Helge Larsen/PI-redaktør	Aktier/tendens: Vestas og DSV i fokus i nervøst marked: (link)
	29/10 08:28 af Helge Larsen/PI-redaktør	Q&A d. 27. nov. kl. 16.
	29/10 08:27 af Helge Larsen/PI-redaktør	God morgen. :-)
	29/10 07:36 af GeorgeBest	Amivantamab har potentiale til at blive stort...
	29/10 00:46 af gentogen	(link)
	29/10 00:45 af gentogen	High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma
	29/10 00:45 af peter12	Ok tak, jeg var ikke klar over at alle de tumor typer udtrykte EGFR og cMet. Interessant ;-)
	28/10 22:55 af peter12	Det lyder forkert. Hvor står det ?
	28/10 22:39 af gentogen	Regarding the new Amivantamab: Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC).
	28/10 21:14 af GeorgeBest	(link) HALOs teknologi anvendes også til Amivantamab sc!
	28/10 18:00 af E L	exactly 100 dkk high -> low . #UselessFacts
	28/10 16:59 af E L	New trial - A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (link)
	28/10 16:37 af Klarussen	Køber i 2050,- vi er der snart ;-)
	28/10 15:26 af Bulder	Belamaf på dansk (link)
	28/10 15:26 af Helge Larsen/PI-redaktør	Ses vi kl. 17? (link)
	28/10 15:23 af Bulder	Professor ærgrer sig over Medicinrådets afvisning af Dar MPV (link)
	28/10 15:08 af E L	PRAC agenda: 5.3.4. Carfilzomib - KYPROLIS (CAP) - EMEA/H/C/003790/II/0045, Orphan Applicant: Amgen Europe B.V. Scope: Extension of existing indication to include combination of Kyprolis (carfilzomib) with daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP